Transcode Therapeutics, Inc.
Transcode Therapeutics, Inc. is listed today as TransCode Therapeutics, Inc.: market value, financials and filings are on its company page.
Funding rounds
0 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Dec 2024 | $8 M | Private placement after listing | $2 to $10 million | equity, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Transcode Therapeutics, Inc. had no revenue when it filed its newest notice of a funding round (Dec 2024).
SEC Form D (revenue range) · Dec 2024
The industry group it chose in its notices: Biotechnology.
SEC Form D · Dec 2024
Products and services#
No products or services of Transcode Therapeutics, Inc. are on record.
Investors#
2 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| CK Life Sciences Intl (Holdings) Inc | Company | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2026) | SEC Form 3 |
| Defj, LLC | Other | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2026) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.
Largest shareholders today
Institutions holding TransCode Therapeutics, Inc. shares, as of Sep 30, 2026.
- Yorkville Advisors Global, LP$0 M0.45%
- Citadel Advisors LLC$0 M0.06%
- Vanguard Capital Management LLC$0 M0.04%
- Vanguard Fiduciary Trust Co$0 M0.02%
- UBS Group AG$0 M0.02%
- Tower Research Capital LLC (TRC)$0 M0.01%
- Osaic Holdings, Inc.$0 M0.00%
- Robinhood Markets, Inc.$0 M0.00%
- Wells Fargo & Company/mn$0 M0.00%
- SBI Securities Co., Ltd.$0 M0.00%
- FMR LLC$0 M0.00%
- IFP Advisors, Inc$0 M0.00%
- Northwestern Mutual Wealth Management Co$0 M0.00%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Thomas A. Fitzgerald | Executive officer | Dec 2024 |
| Erik A. Manting | Director | Dec 2024 |
| Magda A. Marquet | Director | Dec 2024 |
| Philippe A. Calais | Director | Dec 2024 |
| Thomas A. Fitzgerald | Director | Dec 2024 |
Went public since 2021. Its SEC number is that of a company listed on a stock exchange.